12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Chugai sales and marketing update

Chugai launched subcutaneous Actemra tocilizumab in Japan to treat rheumatoid arthritis that does not respond sufficiently to at least one existing therapies. The recommended dose is a 162 mg injection every two weeks and the National Health Index...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >